140 related articles for article (PubMed ID: 20047135)
1. Genetic polymorphisms of GSTP1 related to response to 5-FU-oxaliplatin-based chemotherapy and clinical outcome in advanced colorectal cancer patients.
Jun L; Haiping Z; Beibei Y
Swiss Med Wkly; 2009 Dec; 139(49-50):724-8. PubMed ID: 20047135
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer.
Li QF; Yao RY; Liu KW; Lv HY; Jiang T; Liang J
J Korean Med Sci; 2010 Jun; 25(6):846-52. PubMed ID: 20514304
[TBL] [Abstract][Full Text] [Related]
3. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer.
Stoehlmacher J; Park DJ; Zhang W; Groshen S; Tsao-Wei DD; Yu MC; Lenz HJ
J Natl Cancer Inst; 2002 Jun; 94(12):936-42. PubMed ID: 12072547
[TBL] [Abstract][Full Text] [Related]
4. Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients.
Kweekel DM; Gelderblom H; Antonini NF; Van der Straaten T; Nortier JW; Punt CJ; Guchelaar HJ
Eur J Cancer; 2009 Mar; 45(4):572-8. PubMed ID: 19084393
[TBL] [Abstract][Full Text] [Related]
5. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.
Stoehlmacher J; Park DJ; Zhang W; Yang D; Groshen S; Zahedy S; Lenz HJ
Br J Cancer; 2004 Jul; 91(2):344-54. PubMed ID: 15213713
[TBL] [Abstract][Full Text] [Related]
6. GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group.
Kweekel DM; Koopman M; Antonini NF; Van der Straaten T; Nortier JW; Gelderblom H; Punt CJ; Guchelaar HJ
Br J Cancer; 2008 Oct; 99(8):1316-21. PubMed ID: 18797455
[TBL] [Abstract][Full Text] [Related]
7. GSTP1, ERCC1 and ERCC2 polymorphisms, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in colorectal cancer in Chinese population.
Li HY; Ge X; Huang GM; Li KY; Zhao JQ; Yu XM; Bi WS; Wang YL
Asian Pac J Cancer Prev; 2012; 13(7):3465-9. PubMed ID: 22994779
[TBL] [Abstract][Full Text] [Related]
8. Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes.
Inada M; Sato M; Morita S; Kitagawa K; Kawada K; Mitsuma A; Sawaki M; Fujita K; Ando Y
Int J Clin Pharmacol Ther; 2010 Nov; 48(11):729-34. PubMed ID: 20979931
[TBL] [Abstract][Full Text] [Related]
9. Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome.
Le Morvan V; Smith D; Laurand A; Brouste V; Bellott R; Soubeyran I; Mathoulin-Pelissier S; Robert J
Pharmacogenomics; 2007 Dec; 8(12):1693-703. PubMed ID: 18085999
[TBL] [Abstract][Full Text] [Related]
10. [Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy].
Liang J; Li QF; Yao RY; Lü HY; Jiang J; Sun YY; Song SA; Jiang T
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):515-9. PubMed ID: 21029695
[TBL] [Abstract][Full Text] [Related]
11. Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy.
Kanai M; Yoshioka A; Tanaka S; Nagayama S; Matsumoto S; Nishimura T; Niimi M; Teramukai S; Takahashi R; Mori Y; Kitano T; Ishiguro H; Yanagihara K; Chiba T; Fukushima M; Matsuda F
Cancer Epidemiol; 2010 Apr; 34(2):189-93. PubMed ID: 20308030
[TBL] [Abstract][Full Text] [Related]
12.
Stojkovic Lalosevic M; Coric V; Pekmezovic T; Simic T; Pavlovic Markovic A; Pljesa Ercegovac M
Medicina (Kaunas); 2024 Mar; 60(4):. PubMed ID: 38674199
[No Abstract] [Full Text] [Related]
13. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.
Etienne-Grimaldi MC; Milano G; Maindrault-Goebel F; Chibaudel B; Formento JL; Francoual M; Lledo G; André T; Mabro M; Mineur L; Flesch M; Carola E; de Gramont A
Br J Clin Pharmacol; 2010 Jan; 69(1):58-66. PubMed ID: 20078613
[TBL] [Abstract][Full Text] [Related]
14. Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma.
Chen YC; Tzeng CH; Chen PM; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
Cancer Sci; 2010 Feb; 101(2):530-5. PubMed ID: 19922504
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer.
Lv H; Li Q; Qiu W; Xiang J; Wei H; Liang H; Sui A; Liang J
Pathol Oncol Res; 2012 Oct; 18(4):1009-14. PubMed ID: 22549274
[TBL] [Abstract][Full Text] [Related]
16. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy.
Lecomte T; Landi B; Beaune P; Laurent-Puig P; Loriot MA
Clin Cancer Res; 2006 May; 12(10):3050-6. PubMed ID: 16707601
[TBL] [Abstract][Full Text] [Related]
17. Ile105Val GSTP1 polymorphism and susceptibility to colorectal carcinoma in Bulgarian population.
Vlaykova T; Miteva L; Gulubova M; Stanilova S
Int J Colorectal Dis; 2007 Oct; 22(10):1209-15. PubMed ID: 17404745
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
Huang ZH; Hua D; Du X
Cancer Chemother Pharmacol; 2009 Oct; 64(5):1001-7. PubMed ID: 19247656
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.
Kwon HC; Roh MS; Oh SY; Kim SH; Kim MC; Kim JS; Kim HJ
Ann Oncol; 2007 Mar; 18(3):504-9. PubMed ID: 17322540
[TBL] [Abstract][Full Text] [Related]
20. GSTP1
Walia HK; Singh N; Sharma S
Hum Exp Toxicol; 2021 Dec; 40(12_suppl):S739-S752. PubMed ID: 34780261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]